Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of mavodelpar (REN001) in primary mitochondrial myopathy
2021-003471-34Phase 2Terminated
- Sponsor
- Reneo Pharmaceuticals
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavodelpar in primary mitochondrial myopathies (PMM) and Mitochondrial myopathies (MM), sponsored by Reneo Pharmaceuticals. Primary endpoint: Primary long-term safety and tolerability of mavodelpar (REN001). Started Sep 2021; status: terminated.
02
Drugs
mavodelpar
03
Conditions
primary mitochondrial myopathies (PMM)Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on 2021-003471-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003471-34.